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to the acceptance of environmental effects on behav- The past year has seen the extremes of success and
setbacks in the infant field of gene therapy. Overshad-ioral in the 1950s and 60s, and now back again. The
chapter ends, though, with a soporific flowchart de- owed by the initial occurrences of serious complications
reported in gene therapy trials was the first report sug-picting the scientific process by which one teases out
genetic and environmental influences on behavioral gesting real success in the use of this technology for the
treatment of a monogenic disorder (Carazzana-Calvo ettraits. Stephanie Sherman and Irwin Waldman then pick
up the torch and succinctly describe the statistical ap- al., Blood 94, 367a, 1999). In addition to ongoing criti-
cisms of the focus on human trials in this area by someproaches used to find genes involved in behavioral traits.
For me, the strongest feature of the book was the in the scientific community, the alleged oversights in
the conduct of specific trials and deficiencies in patienttwo chapters (by Mark Rothstein and Lori Andrews) that
dealt directly with the legal implications of behavioral safeguards at several prominent academic centers has
been a setback for the field as a whole. The field stillgenetics. Indeed as much of this topic was new to me,
I could easily have read an entire book on the subject. suffers from unrealistic expectations encouraged in part
by some ªgene therapistsº in the 1980s. The focus onBehavior genetics in the context of the criminal justice
system is a particularly compelling issue. If we embrace gene therapy technology has overshadowed truly re-
markable advances made over the last two decades ingenetic determinism, or for that matter, cultural deter-
minism, where is the room for free will? Culpability in the use of cellular therapies, particularly bone marrow
transplantation and adoptive immunotherapy. However,criminal law requires a voluntary wrongful act and the
mental state to realize that the act is wrongful. If a ge- there can be little doubt that steady progress has been
netic defense is used, other issues are raised as well. made in the technology of gene transfer over this same
Who will pay for the genetic testing if the defense grasps time period, and that the application of gene transfer
at genetic straws? If a jury decides that a defendant is technology to the treatment of human disease will be-
innocent on the grounds of genetic predisposition, what come an important component of medical therapies in
are the implications for others with similar genetic pre- the future.
disposition? Will they be stigmatized or feared or even The underlying theme of Ex Vivo Cell Therapy is that
kept under surveillance? the use of cells and genes in human therapy represents
While many of the authors are correct to point out a sufficiently complicated application as to require work-
epigenetic and environmental influences on behavior, ing collaborations between clinicians, biologists, engi-
only one took great pains to argue against genetic re- neers, and technicians. The multiauthored chapters of
ductionism. In his chapter, Kenneth Schaffner asks this book thus attempt to provide a broad overview of
whether any behavioral trait can have a purely genetic the current knowledge of hematopoiesis, immunology,
explanation and goes on to answer ªno.º His argumentÐ and transplantation biology, as well as the state of the
that genes encode proteins which interact with other art technologies of vectors, hematopoietic cell separa-
proteins, and that neurons, not genes, control behav- tion and purification, and cell expansion using ªclinical
iorÐstruck me as clumsy and semantic. gradeº bioreactors. The book will be useful to anyone
Multiauthor compilations such as this one inevitably whose expertise is in one of these interdependent fields.
suffer from a number of problems. The writing is spotty, The chapters vary in details and in quality, with the
and there is considerable overlap between some essays. inevitable overlap in some areas (particularly noticeable
At least two authors describe the circuitous history of in multiple chapters which address ex vivo expansion
behavioral studies on schizophrenia, for example. How- of hematopoietic stem cells).
ever, the most dissatisfying aspect of the book is that Hematopoiesis is the process in which billions of leu-
the most recent literature citations are from 1997, while kocytes, erythrocytes, platelets, immune effector cells,
the publication date is 1999. Since the reader is now and the other cellular constituents of the blood are pro-
primed to care about the genetics of schizophrenia, she duced every hour of an individual's lifetime. This enor-
wants to know ªhow did it all turn out in the end?º mous cell production is accomplished within narrow
Despite these flaws there is a place on every human limits of normal cell numbers found in the blood and
geneticists bookshelf for Behavioral Genetics. Not only tissues and yet bone marrow production of blood cells
are parts of it well worth reading, it is chock full of must be able to increase rapidly in response to stress
illustrative annotations and references. and insult. Beginning with the first description of the
colony-forming cells (both in vitro and in vivo) that de-
Jane Gitschier fined hematopoietic progenitor cells in the 1960s, the
Howard Hughes Medical Institute understanding of proteins controlling the growth and
Department of Medicine differentiation of these cells has steadily increased. Sig-
University of California, San Francisco nificant therapeutic reagents have already arisen from
San Francisco, California 94143 this understanding. More recently, the use of molecular
and cell biological methods as well as gene targeting
methods have also begun to elucidate the pathways
involved in receptor signaling and transcriptional regula-
tion of the lineage-specific genes that determine cellCells and Genes in Molecular
fate of blood cells. In spite of this progress, the factorsTherapeutics
that regulate homeostasis and differentiation of hemato-
poietic stem cells (the most primitive cells in bone mar-Ex Vivo Cell Therapy
Edited by Klaus Schindhelm and Robert Nordon row from which all blood cells are derived) are to date
largely unknown.London: Academic Press (1999). 356 pp. $79.95
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In superb initial chapters, pathways involved in growth cellsº and passive elimination of contaminating tumor
factor receptor signaling in hematopoietic cells are dis- or effector cells. Cell separation, by purifying a rare
cussed, including JAK/STAT, Ras, phospholipase C, target cell population, provides the added benefit of
and recently described inhibitory pathways. Also, the reducing the amount of reagents and simplifying manip-
transcriptional regulation of genes required for hemato- ulations (and therefore potential complications) required
poietic cell differentiation, such as SCL, GATA, and for downstream processes. The goals of cell expansion
AML-1, is reviewed. Increasingly, as in other cell sys- include both manipulating the cellular constituents of
tems, cell adhesion is becoming appreciated as playing the final cell product and facilitation of transplants using
a role in signaling (not only localization) in hematopoietic a limited initial number of cells. Clearly the efficacy of
cells; this topic is covered in several additional chapters. these emerging technologies is yet to be shown in the
Conceptually, these chapters build a foundation for un- clinic. The regulatory aspects of cell purification and
derstanding both future targets of molecular interven- expansion technology are discussed. Commercial sys-
tions and the microenvironment requirements for large- tems of cell purification and cell expansion are covered,
scale manipulations of hematopoietic cell products. although this information is derived from scientists at
Over the last 30 years there has been a significant only two biotechnology companies while several other
increase in the use of bone marrow transplantation for relevant proprietary approaches are not discussed.
the treatment of malignant, genetic, and in some cases Gene delivery technology, including virus vectors, li-
autoimmune diseases. Increasingly, bone marrow cells posome, particle-mediated, electroporation, and direct
are being replaced with mobilized peripheral blood or DNA injection are reviewed. To accomplish this in limited
umbilical cord blood as sources of transplantable stem space required a brief treatment of each technology
cells. The use of allogeneic, autologous, and cord blood covering basics without significant details. Advantages
transplants is reviewed in helpful middle chapters. The and disadvantages of each technology are noted provid-
authors have done, with rare exceptions, a nice job of ing a useful guideline to those not currently in the field.
summarizing the use, advantages, and disadvantages No discussion of regulatory issues as these relate to
of each of these approaches in current therapies. In so human gene therapy trials is present. Workers in the
doing, the chapters provide a brief overview of increas- field will recognize that these regulations are significant
ingly complex data from multiple sources with respect in both volume and detail, but their inclusion at least in
to outcomes and complications. Two noticeable over- summary form would have added to the overall use-
sights are the lack of discussion of the emerging use of fulness of this book.
haploidentical (usually parenteral or sibling) transplants Understanding the molecular processes that control
in the treatment of malignant disesase and the use of cell growth and differentiation is a major goal of cell and
so-called ªminiº or submyeloablative transplants, which molecular biologists. Application of this knowledge to
may have an enormous impact on the future treatment defining the molecular defects causing human diseases
of nonmalignant diseases. has been the task of scientists in the past 20 years,
Cellular adoptive immunotherapy entails the transfer beginning with the characterization of the molecular ba-
of effector cells of the immune system, usually CD4 or sis of hemoglobinopathies. Over the next several de-
CD8 lymphocytes for the treatment of malignant dis- cades the development of strategies to repair the cellu-
eases or infections. Remarkable progress has been lar systems affected by genetic mutations will be an
made in this area, including development of effective ongoing goal. This book provides a compact review of
adoptive transfer methods to treat leukemia, Epstein- the basic biology of hematopoiesis and technologies
Barr virus (EBV)-associated lymphoma and melanoma. being developed to manipulate hematopoietic cells ei-
Additional applications include treatment of serious, of- ther to eliminate diseased cells or to restore and aug-
ten fatal, EBV and cytomegalovirus infections in the im- ment normal function to the blood system.
munocompromised host. In another excellent chapter,
the basic biology of lymphocyte-mediated immunity is
David A. Williamsdiscussed, and this and other clinical applications are
Howard Hughes Medical Institutereviewed, including data on ongoing clinical trials. Fu-
ture applications in human immunodeficiency virus (HIV) Herman B Wells Center for Pediatric Research
treatment are considered in light of the ability of natural- Indiana University School of Medicine
host T cell response to only partially control HIV virus Indianapolis, Indiana 46202
replication. Such future applications may well require
genetic modification of T lymphocytes. Ex vivo ex-
panded dendritic cells may also prove useful in future
therapies.
Prokaryotic Genomes:Success of cellular and gene therapies in the clinical
setting will require translating laboratory-based meth- The Hidden Code
ods into cell production and modification processes in
large scale with standards of safety similar to other ther- Organization of the Prokaryotic Genome
apeutics. In the latter chapters of this book, the editors Edited by Robert L. Charlebois
have attempted to compile several chapters reviewing Washington, D.C.: ASM Press (1999). 394 pp. $79.95
core technologies required for clinical applications of
ex vivo cell therapies. These technologies include cell
It is evident that biology has entered a new period, some-separation, cell expansion, and gene modification. The
goals of cell separation include selection for ªtarget times called the genomics era. Genomic technologies
